Abbott Laboratories Stock - analyst views and operations midyear
17.06.2026 - 18:35:01 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/17/2026, 18:34 CET. Details in the imprint.
Abbott Laboratories (US0028241000) remains a core healthcare name for many global portfolios. With no new earnings or regulatory filings today, the focus turns to the current analyst consensus on the stock and the operational mix behind the US-based medical products group.
All news and analysis on Abbott Laboratories stock
Background information, prior earnings reports and market data on Abbott Laboratories stock are bundled on the ad-hoc-news topic page and the group's own investor portal.
How analysts value Abbott today
Analyst houses regularly update their models for Abbott Laboratories, tracking earnings from its diagnostics, medical devices, nutrition and established pharmaceuticals divisions. Consensus data compiled on major financial portals typically aggregates 20 to 30 analyst opinions for the stock at any given time.
These consensus snapshots usually include the distribution of Buy, Hold and Sell ratings, a 12-month average price target and expected growth for revenue and earnings per share over the next two to three years. For many investors, this serves as a reference point alongside their own assessment of Abbott's balance sheet and cash generation.
Consensus assumptions on growth and margins
While the exact figures differ slightly among data providers, most consensus collections cluster around mid-single-digit to high-single-digit annual revenue growth for Abbott in the coming years, reflecting a mix of mature product lines and newer growth platforms. Diagnostics and cardiovascular medical devices often feature prominently in growth estimates.
On profitability, analysts generally factor in stable to modestly improving operating margins, supported by product mix improvements and ongoing cost discipline. At the same time, they watch closely for pricing pressure in diagnostics and nutrition, as well as for currency effects given Abbott's broad international footprint.
What drives analyst rating changes
Analyst rating and price-target changes for Abbott are typically triggered by concrete events rather than day-to-day trading moves. Quarterly earnings that materially beat or miss expectations, guidance revisions from management or significant regulatory milestones for key products often prompt updated research notes.
Mergers and acquisitions, changes to capital allocation priorities or shifts in the competitive landscape in areas such as glucose monitoring can also lead to adjustments. Against this backdrop, rating changes are usually framed with clear earnings- or risk-based arguments instead of short-term sentiment.
How Abbott makes its money
Abbott Laboratories generates revenue across four main segments: diagnostics, medical devices, nutrition and established pharmaceuticals. Each contributes differently to growth, margin and geographic diversification, giving the group a relatively balanced earnings profile across developed and emerging markets.
The product behind the stock
One widely recognized Abbott Laboratories product is the FreeStyle Libre continuous glucose monitoring system, which allows people with diabetes to track glucose levels without routine finger-stick testing. The device business adds recurring sensor revenue to Abbott's broader medical technology portfolio.
Where the stock trades today
Abbott Laboratories shares (US0028241000) trade on the New York Stock Exchange; the latest verifiable quote and market capitalization data are available on major financial portals and the exchange's own website as of 06/17/2026, 18:34 CET.
Key facts on Abbott Laboratories stock
- Company: Abbott Laboratories Inc.
- ISIN: US0028241000
- Ticker: ABT
- Venue: NYSE
- Sector / Industry: Health Care / Medical Devices & Diagnostics
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
